A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit.
Open Access
- 1 December 1994
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 180 (6), 2147-2153
- https://doi.org/10.1084/jem.180.6.2147
Abstract
Escherichia coli enterotoxin (LT) and the homologous cholera toxin (CT) are A-B toxins that cause travelers' diarrhea and cholera, respectively. So far, experimental live and killed vaccines against these diseases have been developed using only the nontoxic B portion of these toxins. The enzymatically active A subunit has not been used because it is responsible for the toxicity and it is reported to induce a negligible titer of toxin neutralizing antibodies. We used site-directed mutagenesis to inactivate the ADP-ribosyltransferase activity of the A subunit and obtained nontoxic derivatives of LT that elicited a good titer of neutralizing antibodies recognizing the A subunit. These LT mutants and equivalent mutants of CT may be used to improve live and killed vaccines against cholera and enterotoxinogenic E. coli.Keywords
This publication has 32 references indexed in Scilit:
- An oral B subunit: whole cell vaccine against choleraVaccine, 1992
- Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin.1992
- The crystal structure of diphtheria toxinNature, 1992
- Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccineThe Lancet, 1991
- Cloning, sequencing, and expression of a gene encoding a 100-kilodalton mosquitocidal toxin from Bacillus sphaericus SSII-1Journal of Bacteriology, 1991
- Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coliNature, 1991
- H-2-unrestricted adjuvant effect of cholera toxin B subunit on murine antibody responses to influenza virus haemagglutinin.1991
- Research priorities for diarrhoeal disease vaccines: memorandum from a WHO meeting.1991
- SAFETY, IMMUNOGENICITY, AND EFFICACY OF RECOMBINANT LIVE ORAL CHOLERA VACCINES, CVD 103 AND CVD 103-HgRThe Lancet, 1988
- [24] Production and purification of cholera toxinMethods in Enzymology, 1988